Amgen (NASDAQ:AMGN) Shares Gap Down – Should You Sell?

Amgen Inc. (NASDAQ:AMGN)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $346.25, but opened at $332.52. Amgen shares last traded at $333.18, with a volume of 482,233 shares changing hands.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 beats and raised full-year outlook — Amgen reported Q1 EPS of $5.15 (vs. $4.73 est.) and revenue of $8.62B, and issued FY2026 EPS guidance of $21.70–$23.10, which supports longer?term earnings visibility. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Broad product momentum — Management highlighted 16 drugs with double?digit growth and +4% product sales, showing portfolio resilience versus biosimilar erosion and legacy pressures. Zacks: 16 Drugs Deliver Double-Digit Gains
• Positive Sentiment: Analyst bullishness and higher price target — Goldman Sachs raised its AMGN price target to $425 and maintained a Buy; other analysts reiterated Buys, underpinning upside expectations. Goldman Sachs Raises Price Target to $425
• Neutral Sentiment: Pipeline focus — Management emphasized an expanded MariTide (obesity) development program as a multi?year growth driver; concrete near-term revenue impact is uncertain and will depend on clinical progress and regulatory timelines. Reuters: Sales Rise 4%; MariTide Program
• Neutral Sentiment: Earnings materials and calls available — Full Q1 transcript, slides and call recording provide more detail for investors to model product-level growth and guidance assumptions. Earnings Call Transcript
• Negative Sentiment: FDA proposal to withdraw Tavneos — The FDA has proposed withdrawing Tavneos approval citing alleged clinical?trial data manipulation and untrue statements, raising regulatory, legal and reputational risks that could pressure the stock. FDA Tavneos Proposal
• Negative Sentiment: Investor caution on execution and strategy — Some coverage noted the report was “generally in?line” (not a clear blowout) and that the company’s aggressive push into obesity and other areas adds near?term execution risk; that tone contributed to selling pressure. Amgen Aggressively Expanding in Obesity
• Negative Sentiment: Market impact headline — Broad-market stories noted Amgen was a drag on the Dow amid mixed macro/earnings headlines, which can amplify intraday declines in large-cap pharma names. Nasdaq Leads as Amgen Drags Dow

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $357.23.

Amgen Price Performance

The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market capitalization of $176.49 billion, a PE ratio of 22.97, a P/E/G ratio of 3.34 and a beta of 0.47. The stock’s 50-day moving average is $358.07 and its 200 day moving average is $340.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.42. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm posted $4.90 EPS. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.16 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Simplicity Wealth LLC grew its position in Amgen by 7.4% during the 1st quarter. Simplicity Wealth LLC now owns 4,737 shares of the medical research company’s stock worth $1,667,000 after purchasing an additional 326 shares during the last quarter. Candriam S.C.A. grew its position in Amgen by 0.9% during the 1st quarter. Candriam S.C.A. now owns 395,351 shares of the medical research company’s stock worth $139,104,000 after purchasing an additional 3,616 shares during the last quarter. Relyea Zuckerberg Hanson LLC grew its position in Amgen by 5.4% during the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 1,449 shares of the medical research company’s stock worth $510,000 after purchasing an additional 74 shares during the last quarter. OMC Financial Services LTD grew its position in Amgen by 2.2% during the 1st quarter. OMC Financial Services LTD now owns 5,465 shares of the medical research company’s stock worth $1,923,000 after purchasing an additional 120 shares during the last quarter. Finally, Manning & Napier Advisors LLC grew its position in Amgen by 86.6% during the 1st quarter. Manning & Napier Advisors LLC now owns 181 shares of the medical research company’s stock worth $63,000 after purchasing an additional 84 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.